tbuckley/cabot-search huggingface dataset:
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Authors: Emily M. Hartsell, Mark N. Gillespie, Raymond J. Langley
Journal: European Respiratory Journal (2021)

<b>Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets.</b>https://bit.ly/2XkJeU8
Fabricating Tissues In Situ with the Controlled Cellular Alignments
Authors: Chuanjiang He, Mengxue Liu, Deming Jiang, Jianguo Wu, Chunlian Qin, Tao Liang, Pan Wu, Chunmao Han, Liquan Huang, K. Jimmy Hsia, Ping Wang
Journal: Advanced Healthcare Materials (2021)

Tissue engineering techniques have enabled to replicate the geometrical architecture of native tissues but usually fail to reproduce their exact cellular arrangements during the fabricating process, while it is critical for manufacturing physiologically relevant tissues. To address this problem, a "sewing-like" method of controlling cellular alignment during the fabricating process is reported here. By integrating the stretching step into the fabricating process, a static mechanical environment is created which, in turn, regulates the subsequent cellular alignment, elongation, and differentiation in the generated tissues. With this method, patterned cellular constructs can be fabricated with controlled cellular alignment. Moreover, this method shows a potent capability to fabricate physiologically relevant skeletal muscle constructs in vitro by mechanically inducing myoblast fusion and maturation. As a potential clinical application, aligned myofibers are directly fabricated onto injured muscles in vivo, which repair the damaged tissues effectively. This study shows that the "sewing-like" method can produce engineered tissues with precise control of cellular arrangements and more clinically viable functionalities.
Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases
Authors: Jennifer Abbasi
Journal: JAMA (2021)

The good news: about 9 out of 10 patients with a chronic inflammatory disease (CID) produced antibodies against SARS-CoV-2 after full vaccination in a recent study. The not-so-good news: their antibody levels were about a third as strong as those observed in a group of volunteers without CIDs.
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Authors: Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson
Journal: Pharmacological Reviews (2021)

Parkinson disease (PD) used to be considered a nongenetic condition. However, the identification of several autosomal dominant and recessive mutations linked to monogenic PD has changed this view. Clinically manifest PD is then thought to occur through a complex interplay between genetic mutations, many of which have incomplete penetrance, and environmental factors, both neuroprotective and increasing susceptibility, which variably interact to reach a threshold over which PD becomes clinically manifested. Functional studies of PD gene products have identified many cellular and molecular pathways, providing crucial insights into the nature and causes of PD. PD originates from multiple causes and a range of pathogenic processes at play, ultimately culminating in nigral dopaminergic loss and motor dysfunction. An in-depth understanding of these complex and possibly convergent pathways will pave the way for therapeutic approaches to alleviate the disease symptoms and neuroprotective strategies to prevent disease manifestations. This review is aimed at providing a comprehensive understanding of advances made in PD research based on leveraging genetic insights into the pathogenesis of PD. It further discusses novel perspectives to facilitate identification of critical molecular pathways that are central to neurodegeneration that hold the potential to develop neuroprotective and/or neurorestorative therapeutic strategies for PD. <h3>Significance Statement</h3> A comprehensive review of PD pathophysiology is provided on the complex interplay of genetic and environmental factors and biologic processes that contribute to PD pathogenesis. This knowledge identifies new targets that could be leveraged into disease-modifying therapies to prevent or slow neurodegeneration in PD.
P55.03 Results of The First Survey Using EORTC QLQ INFO25 on Information Acquisition and Satisfaction of Lung Cancer Patients in Japan
Authors: T. Takahama, H. Shimizu, H. Kaneda, H. Horinouchi, K. Watanabe, T. Yoshida, K. Hasegawa, K. Onishi, K. Yoshimura, T. Sawa, A. Gemma
Journal: Journal of Thoracic Oncology (2021)
12P Molecular features of KRAS mutant NSCLC: Weaving a future score for immune-checkpoint inhibitors (ICI)
Authors: M. Dorta Suarez, B. Jimenez Munarriz, A. Del Barrio, G. Garcia Ledo, R. Blanco Blanco, E. Conde Gallego, S. Hernandez Prieto, F. Lopez Rios, A. Cubillo Gracián
Journal: Annals of Oncology (2021)
OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
Authors: M. Provencio, E. Nadal, A. Insa, M.R. García Campelo, D. Pereiro, M. Domine, M. Majem, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro, M. Cobo, G. López Vivanco, E. Del Barco, R. Bernabé, N. Viñolas, I. Barneto, S. Viteri, E. Pereira, A. Royuela, M. Casarrubios, C. Salas, E.R. Parra, I. Wistuba, V. Calvo, R. Laza - Briviesca, A. Romero, B. Massuti, A. Cruz
Journal: Journal of Thoracic Oncology (2021)
Cardiac Amyloidosis
Authors: Ronald Witteles, Bonnie Ky
Journal: JACC CardioOncology (2021)

CardioOncologyThe tipping point is that magic moment when an idea, trend, or social behavior crosses a threshold, tips, and spreads like wildfire.-Claire Dederrer (1)"O f all areas, why amyloidosis?"This was the near-universal reaction I (R.W.) received when I told my colleagues that I wanted to focus my time, upon completion of fellowship, on amyloidosis.My rationale was simple.Amyloidosis felt like the only disease in the field of heart failure that we could diagnose but do little about-and that seemed like an opportunity.
Abstract P249: Differential Response to a Lifestyle Intervention Between Parents and Non-parents
Authors: Carolyn T Bramante, Rachel L Thornton, Scott J Pilla, Nisa Maruthur, Maya Venkataramani, Jeanne M Clark
Journal: Circulation (2018)

Background: Understanding and preventing cardiovascular disease among parents is important for reducing intergenerational transfer of cardiovascular disease. Prior research has not examined the effect of lifestyle interventions among parents compared to non-parents. We performed a retrospective analysis of the Look AHEAD (Action for Health in Diabetes) trial to assess outcome differences between participants with children younger than 18 years living in the home (referred to as parents) and those without (referred to as non-parents). Methods: Look AHEAD randomized adults aged 45-75 years with type 2 diabetes and BMI&gt;25kg/m 2 to an intensive lifestyle intervention aimed at weight loss, or to a diabetes support and education (control) arm. We examined effects of the intervention at 12 months on objectively measured change in weight (percent of baseline) and cardiovascular risk factors, and change in self-reported dietary intake. To determine whether parenting modified these outcomes, we used linear regression (continuous outcomes) or logistic regression (categorical outcomes) with a multiplicative interaction term for parenting status and treatment arm, adjusted for sociodemographic and clinical characteristics. Modeled results of the interaction are presented. Results: Among 4,547 participants at baseline, 699 (15%) were parents. Parents were younger than non-parents (54.1 vs 59.0 years, p&lt;0.001); more likely to be black (20.2% vs 15.4%) or Hispanic (19.3% vs 12.5%), p&lt;0.001; and more likely to have a professional degree (6.7% vs 5.0%) or no high school education (8.5% vs 5.7%), p&lt;0.001. Age-adjusted baseline prevalence of chronic disease was similar for parents and non-parents. In response to the intervention (treatment minus control arm), parents lost less weight than non-parents, (-7.1% vs -8.3%, p=0.019); and had less improvement in waist circumference (-5.6cm vs -7.2cm, p=0.008). There were trends towards parents having less improvement in triglycerides (-6.0mg/dl vs -17.7mg/dl, p=0.060) and servings of sweets/fats consumed per day (-0.4 vs -0.6, p=0.055). Conclusions: In a clinical trial of an intensive lifestyle intervention for patients with type 2 diabetes, participants with children living in the home had less favorable response to the intervention for change in weight and waist circumference. More research is needed to understand the association of parenthood with health behaviors to optimize cardiovascular risk reduction interventions for parents.
P48.17 Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
Authors: J. Nieva, A. Taylor, L. Servidio, P. Sun, P. Okhuoya, P. Horvat, E. Tolani, K. Magee, R. Mathur, S. Balakrishna
Journal: Journal of Thoracic Oncology (2021)
Medicare &amp;amp; You 2001
Authors: N A DeParle
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence
Authors: Sarah Moody, Sergey Senkin, S. M. Ashiqul Islam, Jingwei Wang, Dariush Nasrollahzadeh, Ricardo Cortez Cardoso Penha, Stephen Fitzgerald, Erik N. Bergstrom, Joshua Atkins, Yudou He, Azhar Khandekar, Karl Smith-Byrne, Christine Carreira, Valerie Gaborieau, Calli Latimer, Emily Thomas, Irina Abnizova, Pauline E. Bucciarelli, David Jones, Jon W. Teague, Behnoush Abedi-Ardekani, Stefano Serra, Jean-Yves Scoazec, Hiva Saffar, Farid Azmoudeh-Ardalan, Masoud Sotoudeh, Arash Nikmanesh, Hossein Poustchi, Ahmadreza Niavarani, Samad Gharavi, Michael Eden, Paul Richman, Lia S. Campos, Rebecca C. Fitzgerald, Luis Felipe Ribeiro, Sheila Coelho Soares-Lima, Charles Dzamalala, Blandina Theophil Mmbaga, Tatsuhiro Shibata, Diana Menya, Alisa M. Goldstein, Nan Hu, Reza Malekzadeh, Abdolreza Fazel, Valerie McCormack, James McKay, Sandra Perdomo, Ghislaine Scelo, Estelle Chanudet, Laura Humphreys, Ludmil B. Alexandrov, Paul Brennan, Michael R. Stratton
Journal: Nature Genetics (2021)
Needle‐free epicutaneous For t 2 DNA vaccine is effective for preventing and treating biting midge <i>Forcipomyia taiwana</i> allergy in a murine model
Authors: Mey‐ Fann Lee, Chi‐Sheng Wu, Shyh‐Jye Lin, Yi‐Hsing Chen
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
35P Increased sensitivity to olaparib by BRCA1/2 knockdown using a CRISPR/Cas9-mediated knock-in method in pancreatic cancer cell lines
Authors: A. Witz, J. Dardare, M. Husson, A. Francois, J-L. Merlin, P. Gilson, A. Harlé
Journal: Annals of Oncology (2021)
Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland
Authors: Utkarsh Agrawal, Amaya Azcoaga-Lorenzo, Adeniyi Francis Fagbamigbe, Eleftheria Vasileiou, Paul Henery, Colin R Simpson, Sarah J Stock, Syed Ahmar Shah, Chris Robertson, Mark Woolhouse, Lewis D Ritchie, Aziz Shiekh, Ewen M Harrison, Annemarie B Docherty, Colin McCowan
Journal: Journal of the Royal Society of Medicine (2021)

Objectives We investigated the association between multimorbidity among patients hospitalised with COVID-19 and their subsequent risk of mortality. We also explored the interaction between the presence of multimorbidity and the requirement for an individual to shield due to the presence of specific conditions and its association with mortality. Design We created a cohort of patients hospitalised in Scotland due to COVID-19 during the first wave (between 28 February 2020 and 22 September 2020) of the pandemic. We identified the level of multimorbidity for the patient on admission and used logistic regression to analyse the association between multimorbidity and risk of mortality among patients hospitalised with COVID-19. Setting Scotland, UK. Participants Patients hospitalised due to COVID-19. Main outcome measures Mortality as recorded on National Records of Scotland death certificate and being coded for COVID-19 on the death certificate or death within 28 days of a positive COVID-19 test. Results Almost 58% of patients admitted to the hospital due to COVID-19 had multimorbidity. Adjusting for confounding factors of age, sex, social class and presence in the shielding group, multimorbidity was significantly associated with mortality (adjusted odds ratio 1.48, 95%CI 1.26–1.75). The presence of multimorbidity and presence in the shielding patients list were independently associated with mortality but there was no multiplicative effect of having both (adjusted odds ratio 0.91, 95%CI 0.64–1.29). Conclusions Multimorbidity is an independent risk factor of mortality among individuals who were hospitalised due to COVID-19. Individuals with multimorbidity could be prioritised when making preventive policies, for example, by expanding shielding advice to this group and prioritising them for vaccination.
P56.04 Pathological Features &amp; Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A
Authors: F. Kraus, G. Nilius, S. Bölükbas, I. Stöver, A. Koziorowski, F. Grabellus, D. Christoph
Journal: Journal of Thoracic Oncology (2021)
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, p<scp>lacebo‐controlled</scp> study (<scp>IRON</scp>‐<scp>CLAD</scp>)
Authors: Tamta Makharadze, Ralph Boccia, Anna Krupa, Nicole Blackman, David H. Henry, Jeffrey A. Gilreath
Journal: American Journal of Hematology (2021)

Erythropoiesis-stimulating agents (ESA) are effective for chemotherapy-induced anemia (CIA) but associated with serious adverse events. Safer alternatives would be beneficial in this population. The efficacy and safety of ferric carboxymaltose (FCM) as monotherapy for CIA was evaluated. This Phase 3, 18-week, double-blind, placebo-controlled study randomized adults with ≥ 4 weeks of chemotherapy remaining for treatment of nonmyeloid malignancies with CIA to FCM (two 15 mg/kg infusions 7 days apart; maximum dose, 750 mg single/1500 mg total) or placebo. The primary efficacy endpoint was percentage of patients with decreases in hemoglobin (Hb) ≥ 0.5 g/dL from weeks 3 to 18; the key secondary efficacy endpoint was change in Hb from baseline to week 18. Inclusion criteria included: (Hb) 8-11 g/dL, ferritin 100-800 ng/mL, and transferrin saturation (TSAT) ≤35%. In 244 patients (n = 122, both groups), the percent of patients who maintained Hb within 0.5 g/dL of baseline from weeks 3 to 18 was significantly higher with FCM versus placebo (50.8% vs. 35.3%; p = 0.01). Mean change in Hb from baseline to week 18 was similar between FCM and placebo (1.04 vs. 0.87 g/dL) but significantly greater with FCM with baseline Hb ≤ 9.9 g/dL (1.08 vs. 0.42 g/dL; p = 0.01). The percent with ≥ 1 g/dL increase from baseline was significantly higher with FCM versus placebo (71% vs. 54%; p = 0.01), occurring in a median 43 versus 85 days (p = 0.001). Common adverse events in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). FCM monotherapy effectively maintained Hb and was well tolerated in CIA.
OA02.04 Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC
Authors: K. Kawasumi, M. Morise, K. Kirita, K. Saeki, H. Kameoka, H. Daga, M. Miyazaki, R. Toyozawa, M. Uoi, M. Harada, S. Tamaki, M. Takeda, K. Fujiwara, T. Yamanaka, K. Goto
Journal: Journal of Thoracic Oncology (2021)
P54.06 The FITNESS Study: Geriatric Assessment, Treatment Toxicity, and Biospecimen Collection Among Older Adults With Lung Cancer
Authors: M. Grogan, J. Benedict, S. Janse, R. Hoyd, N. Williams, M. Naughton, B. Andersen, D. Carbone, E. Paskett, A. Rosko, D. Spakowicz, C. Presley
Journal: Journal of Thoracic Oncology (2021)
Neutrophils in cancer carcinogenesis and metastasis
Authors: Shumin Xiong, Liaoliao Dong, Lin Cheng
Journal: Journal of Hematology & Oncology (2021)

Abstract In recent years, neutrophils have attracted increasing attention because of their cancer-promoting effects. An elevated neutrophil-to-lymphocyte ratio is considered a prognostic indicator for patients with cancer. Neutrophils are no longer regarded as innate immune cells with a single function, let alone bystanders in the pathological process of cancer. Their diversity and plasticity are being increasingly recognized. This review summarizes previous studies assessing the roles and mechanisms of neutrophils in cancer initiation, progression, metastasis and relapse. Although the findings are controversial, the fact that neutrophils play a dual role in promoting and suppressing cancer is undeniable. The plasticity of neutrophils allows them to adapt to different cancer microenvironments and exert different effects on cancer. Given the findings from our own research, we propose a reasonable hypothesis that neutrophils may be reprogrammed into a cancer-promoting state in the cancer microenvironment. This new perspective indicates that neutrophil reprogramming in the course of cancer treatment is a problem worthy of attention. Preventing or reversing the reprogramming of neutrophils may be a potential strategy for adjuvant cancer therapy.
67P Challenges to molecular testing for selecting targeted therapies for oncology patients in India
Authors: V.P.B. Koyyala, P.S. Kulkarni, V. Goel, S.C. Goteti, S. Raj Purohit, A. Jajodia, S.R. Ch, P. Medisetty, P. Goyal, M. La Mantia, C. Dodagoudar, S. Pasricha, S.S. Sen
Journal: Annals of Oncology (2021)
40P MALAT-1/miR-30a-5p competing endogenous (ceRNA) network releases the brakes of immune surveillance in breast cancer through its quadruple targets: PD-L1, MIF, IL-10 and TNF-α
Authors: A. Ramzy, R.A. Youness, T. Manie, A. Sebak, S. Mansour
Journal: Annals of Oncology (2021)
Nanomedicine potentiates mild photothermal therapy for tumor ablation
Authors: Zijun Jiang, Tianyi Li, Hao Cheng, Feng Zhang, Xiaoyu Yang, Shihao Wang, Jianping Zhou, Yang Ding
Journal: Asian Journal of Pharmaceutical Sciences (2021)

The booming photothermal therapy (PTT) has achieved great progress in non-invasive oncotherapy, and paves a novel way for clinical oncotherapy. Of note, mild temperature PTT (mPTT) of 42-45 °C could avoid treatment bottleneck of the traditional PTT, including nonspecific injury to normal tissues, vasculature and host antitumor immunity. However, cancer cells can resist mPTT via heat shock response and autophagy, thus leading to insufficient mPTT monotherapy to ablate tumor. To overcome the deficient antitumor efficacy caused by thermo-resistance of cancer cells and mono mPTT, synergistic therapies towards cancer cells have been conducted with mPTT. This review summarizes the recent advances in nanomedicine-potentiated mPTT for cancer treatment, including strategies for enhanced single-mode mPTT and mPTT plus synergistic therapies. Moreover, challenges and prospects for clinical translation of nanomedicine-potentiated mPTT are discussed.
P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
Authors: S. Chotai, S. Schmid, S. Cheng, L. Zhan, K. Balaratnam, K. Khan, D. Patel, M.C. Brown, W. Xu, P. Moriarty, O. Kaidanovich-Beilin, F.A. Shepherd, A. Sacher, N. Leighl, P. Bradbury, G. Liu
Journal: Journal of Thoracic Oncology (2021)
Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score
Authors: G.M. Aguirre-García, D. Ramonfaur, G. Torre-Amione, M.T. Ramírez-Elizondo, R. Lara-Medrano, J.F. Moreno-Hoyos, E.S. Velázquez-Ávila, C.A. Diaz-Garza, V.M. Sanchez-Nava, F. Castilleja-Leal, G.M. Rhoades, M.F. Martínez-Reséndez
Journal: Pulmonology (2021)

High flow oxygen therapy (HFO) is a widely used intervention for pulmonary complications. Amid the coronavirus infectious disease 2019 (COVID-19) pandemic, HFO became a popular alternative to conventional oxygen supplementation therapies. Risk stratification tools have been repurposed -and new ones developed- to estimate outcome risks among COVID-19 patients. This study aims to provide a simple risk stratification system to predict invasive mechanical ventilation (IMV) or death among COVID-19 inpatients on HFO.Among 529 adult inpatients with COVID-19 pneumonia, we selected unadjusted clinical risk factors for developing the composite endpoint of IMV or death. The risk for the primary outcome by each category was estimated using a Cox proportional hazards model. Bootstrapping was used to validate the results.Age above 62, eGFR under 60 ml/min, room air SpO2 ≤89 % upon admission, history of hypertension, history of diabetes, and any comorbidity (cancer, cardiovascular disease, COPD/ asthma, hypothyroidism, or autoimmune disease) were considered for the score. Each of the six criteria scored 1 point. The score was further simplified into 4 categories: 1) 0 criteria, 2) 1 criterion, 3) 2-3 criteria, and 4) ≥4 criteria. Taking the first category as the reference, risk estimates for the primary endpoint were HR; 2.94 [1.67 - 5.26], 4.08 [2.63 - 7.05], and 6.63 [3.74 - 11.77], respectively. In ROC analysis, the AUC for the model was 0.72.Our score uses simple criteria to estimate the risk for IMV or death among COVID-19 inpatients with HFO. Higher category reflects consistent increases in risk for the endpoint.
P41.02 Surgery for Small Pulmonary NUT Carcinoma: Case Report
Authors: Y. Saito, F. Yokote, K. Takeuchi, T. Honda, S. Numakura, H. Dejima, M. Sakuramachi, Y. Yamauchi, T. Mori, N. Motoi, K. Shiraishi, K. Saito, N. Seki, Y. Sakao, M. Kawamura
Journal: Journal of Thoracic Oncology (2021)